BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 27, 2018
View Archived Issues
Phase II results of JAK1/2 inhibitor baricitinib for the treatment of systemic lupus erythematosus
Read More
Use of autologous adipose-derived regenerative cells for the treatment of severe thermal burns
Read More
Novel small molecule targeting STAT5/6 reverses allergic airway disease in mice
Read More
Kinase inhibitors for familial Parkinson's may work in sporadic disease
Read More
Positive topline results presented for phase IIb study of RTB-101
Read More
PTBP1 identified as a SASP regulator that does not affect the senescence growth arrest
Read More
CFDA approves INDs for Innovent's IBI-101 and IBI-307
Read More
Researchers develop CD41-KO murine model of immune thrombocytopenia
Read More
DSMB recommends early termination of phase III study of Neutrolin owing to efficacy
Read More
New phase III trial explores subcutaneous fixed-dose combination of pertuzumab and trastuzumab
Read More
Otonomy initiates additional phase III trial of Otividex for Meniere's disease
Read More
Phase III studies of KX2-391 in actinic keratosis achieve primary endpoint
Read More
DTX-401 begins phase I/II study for glycogen storage disease type Ia
Read More
Phase I study of BTK inhibitor PRN-2246 confirms CNS exposure and promising tolerability
Read More
Medivir reports promising topline joint structure outcomes from phase IIa extension study of MIV-711
Read More
Chronic treatment with BBB-penetrable EPO analogue shows protective effects in AD mice model
Read More
Proclara advances NPT-189 for systemic amyloidosis and NPT-088 for Alzheimer's
Read More
First data presented from phase I/II study of dolutegravir dispersible tablet pediatric formulation
Read More
Continued virologic suppression in subjects with resistance mutation switching to E/C/F/TAF
Read More
Data presented for the 48-week viral suppression across age categories in the LIVING study
Read More
Viamet Pharmaceuticals describes cytochrome P450 11B2 inhibitors
Read More
Meiji Seika Pharma identifies phosphodiesterase PDE4 inhibitors
Read More
Minoryx Therapeutics patents beta-1 galactosidase mutant chaperones
Read More